Punch & Associates Investment Management Inc. Lowers Holdings in InfuSystem Holdings, Inc. $INFU

Key Points

• Punch & Associates Investment Management Inc. has reduced its stake in InfuSystem Holdings, Inc. by 36.0%, selling 345,000 shares and now holds a total of 614,656 shares.
• InfuSystem's stock was recently downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, while analysts set an average price target of $12.50 for the stock.
• Institutional investors collectively own 71.13% of InfuSystem's shares, indicating strong interest from large funds in the company's stock performance.

Punch & Associates Investment Management Inc. decreased its stake in InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) by 36.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 614,656 shares of the company's stock after selling 345,000 shares during the quarter. Punch & Associates Investment Management Inc. owned approximately 2.92% of InfuSystem worth $3,307,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Wells Fargo & Company MN raised its position in shares of InfuSystem by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,286 shares of the company's stock valued at $78,000 after buying an additional 3,165 shares during the last quarter. Barclays PLC raised its position in shares of InfuSystem by 10.1% in the fourth quarter. Barclays PLC now owns 31,479 shares of the company's stock valued at $266,000 after buying an additional 2,882 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of InfuSystem by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 456,043 shares of the company's stock valued at $3,853,000 after buying an additional 21,697 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of InfuSystem in the fourth quarter valued at about $110,000. Finally, Northern Trust Corp raised its position in shares of InfuSystem by 7.7% in the fourth quarter. Northern Trust Corp now owns 186,741 shares of the company's stock valued at $1,578,000 after buying an additional 13,333 shares during the last quarter. Institutional investors and hedge funds own 71.13% of the company's stock.

InfuSystem Trading Up 1.6%

Shares of INFU traded up $0.16 during trading on Tuesday, reaching $10.42. 316,773 shares of the company traded hands, compared to its average volume of 179,389. InfuSystem Holdings, Inc. has a twelve month low of $4.61 and a twelve month high of $11.04. The stock has a market cap of $212.84 million, a PE ratio of 173.70 and a beta of 1.82. The stock has a 50-day simple moving average of $7.79 and a 200-day simple moving average of $6.44. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50.

Insider Buying and Selling at InfuSystem

In other InfuSystem news, Director Scott Shuda sold 5,752 shares of InfuSystem stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $9.67, for a total transaction of $55,621.84. Following the completion of the sale, the director directly owned 94,000 shares in the company, valued at $908,980. This trade represents a 5.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Roth Capital began coverage on shares of InfuSystem in a research report on Tuesday, July 22nd. They issued a "buy" rating and a $12.00 target price for the company. Wall Street Zen cut shares of InfuSystem from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 14th. Three investment analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock presently has an average rating of "Strong Buy" and a consensus target price of $12.50.

InfuSystem Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.